Xenofon Baraliakos

Oct 5, 2024 | acrjournals.onlinelibrary.wiley.com | Philip Mease |Xenofon Baraliakos |Rheumazentrum Ruhrgebiet |Vinod Chandran

INTRODUCTION Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease characterized by psoriasis of the skin and nails and joint disease affecting the peripheral and/or axial skeleton.1 Most patients with PsA present with multidomain disease requiring individualized treatment.2 Disease activity, previous therapies, prognostic factors (eg, pre-existing structural damage), comorbid conditions, and patient characteristics may influence response to therapy.3 Considering the...

Apr 1, 2024 | acrjournals.onlinelibrary.wiley.com | Xenofon Baraliakos |Mikkel Østergaard

Supporting Information Filename Description art42852-sup-0001-Disclosureform.pdfPDF document, 874.3 KB Disclosure Form art42852-sup-0002-Supinfo.docxWord 2007 document , 420.8 KB Supporting Information S1

Mar 19, 2024 | ard.bmj.com | Andreas Kerschbaumer |Josef S Smolen |Heidi Bertheussen |Xenofon Baraliakos

Methods This SLR was conducted according to the EULAR updated standard operating procedures and based on a protocol developed and approved by the task force.26 To update the evidence from the previous SLR with the data cut on 21 December 2018,24 articles published in English language between 1 January 2018 and 28 December 2022 were searched by an experienced librarian (JWS) using Medline (PubMed), Embase (OVID version), the Cochrane CENTRAL Register of Controlled Trials (Central) and the...

Mar 18, 2024 | ard.bmj.com | Laure Gossec |Andreas Kerschbaumer |Daniel Aletaha |Xenofon Baraliakos

Of the seven OAPs, three remain unchanged, three were reworded and one has been added (overarching principle G). For more information on the thought process leading to the OAPs (unchanged or slightly changed), please refer to the 2015 and 2019 recommendations manuscripts.9 15 Key points from the discussion of the OAPs are addressed in the following:A. Psoriatic arthritis is a heterogeneous and potentially severe disease, which may require multidisciplinary treatment (unchanged).

Oct 4, 2023 | ard.bmj.com | Xenofon Baraliakos |Atul Deodhar |Marina N. Magrey |Walter P. Maksymowych

Safety data for the DBTP have been reported previously and are summarised in table 3.22 At Week 52, ≥1 TEAE was reported for 183 out of 244 (75.0%; EAIR/100 PY: 202.1) patients with nr-axSpA and 249 out of 330 (75.5%; EAIR/100 PY: 200.8) with r-axSpA who had received ≥1 dose of BKZ (table 3).